Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

BJU Int. 2024 Jul;134(1):43-44. doi: 10.1111/bju.16245. Epub 2023 Dec 18.

Authors

Satoru Taguchi¹, Taketo Kawai², Tohru Nakagawa², Haruki Kume¹

Affiliations

¹ Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
² Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.

PMID: 38073020
DOI: 10.1111/bju.16245

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological* / therapeutic use
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / pathology
Disease Progression*
Humans
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology
Urologic Neoplasms / drug therapy
Urologic Neoplasms / pathology

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological